Evaluation of the clinical value of a simple flowmeter in the management of male lower urinary tract symptoms
Study Type – Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low‐cost device, Uflowmeter™, allows men to perform ur...
Saved in:
Published in | BJU international Vol. 109; no. 11; pp. 1690 - 1696 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.06.2012
Wiley-Blackwell Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 1464-4096 1464-410X 1464-410X |
DOI | 10.1111/j.1464-410X.2011.10581.x |
Cover
Abstract | Study Type – Diagnostic (exploratory cohort)
Level of Evidence 3b
What's known on the subject? and What does the study add?
Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low‐cost device, Uflowmeter™, allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS.
OBJECTIVE
•
To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10–15, 15–19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS).
PATIENTS AND METHODS
•
A total of 186 men with LUTS were enrolled in the study.
•
The mean (range) follow‐up was 220 (68–431) days. The men's mean (range) age was 65.5 (46–83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3–39.5) mL/s, mean (range) voided volume 294.8 (151–686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0–303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1–31).
•
The men underwent electronic uroflowmetry (‘clinic uroflowmetry’) and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home (‘home uroflowetry’). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later.
•
Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10–15, 15–19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS.
•
Kaplan–Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP).
RESULTS
•
The home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78–0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0–0.173) in correlating with the mean Qmax of clinic uroflowmetry.
•
Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97–1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83–0.94).
•
The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24–3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23–265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0–73.19).
•
Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log‐rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10–28.64)). The IPSS failed to display the same discriminative capability.
CONCLUSION
•
Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS. |
---|---|
AbstractList | Study Type – Diagnostic (exploratory cohort)
Level of Evidence 3b
What's known on the subject? and What does the study add?
Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low‐cost device, Uflowmeter™, allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS.
OBJECTIVE
•
To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10–15, 15–19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS).
PATIENTS AND METHODS
•
A total of 186 men with LUTS were enrolled in the study.
•
The mean (range) follow‐up was 220 (68–431) days. The men's mean (range) age was 65.5 (46–83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3–39.5) mL/s, mean (range) voided volume 294.8 (151–686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0–303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1–31).
•
The men underwent electronic uroflowmetry (‘clinic uroflowmetry’) and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home (‘home uroflowetry’). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later.
•
Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10–15, 15–19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS.
•
Kaplan–Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP).
RESULTS
•
The home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78–0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0–0.173) in correlating with the mean Qmax of clinic uroflowmetry.
•
Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97–1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83–0.94).
•
The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24–3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23–265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0–73.19).
•
Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log‐rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10–28.64)). The IPSS failed to display the same discriminative capability.
CONCLUSION
•
Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS. Study Type - Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low-cost device, Uflowmeter(™) , allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS.UNLABELLEDStudy Type - Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low-cost device, Uflowmeter(™) , allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS.To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10-15, 15-19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS).OBJECTIVETo show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10-15, 15-19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS).A total of 186 men with LUTS were enrolled in the study. The mean (range) follow-up was 220 (68-431) days. The men's mean (range) age was 65.5 (46-83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3-39.5) mL/s, mean (range) voided volume 294.8 (151-686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0-303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1-31). The men underwent electronic uroflowmetry ('clinic uroflowmetry') and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home ('home uroflowetry'). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10-15, 15-19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS. Kaplan-Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP).PATIENTS AND METHODSA total of 186 men with LUTS were enrolled in the study. The mean (range) follow-up was 220 (68-431) days. The men's mean (range) age was 65.5 (46-83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3-39.5) mL/s, mean (range) voided volume 294.8 (151-686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0-303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1-31). The men underwent electronic uroflowmetry ('clinic uroflowmetry') and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home ('home uroflowetry'). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10-15, 15-19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS. Kaplan-Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP).The home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78-0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0-0.173) in correlating with the mean Qmax of clinic uroflowmetry. Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97-1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83-0.94). The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24-3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23-265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0-73.19). Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log-rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10-28.64)). The IPSS failed to display the same discriminative capability.RESULTSThe home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78-0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0-0.173) in correlating with the mean Qmax of clinic uroflowmetry. Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97-1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83-0.94). The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24-3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23-265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0-73.19). Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log-rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10-28.64)). The IPSS failed to display the same discriminative capability.Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS.CONCLUSIONHome uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS. Study Type - Diagnostic (exploratory cohort) Level of Evidence3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low-cost device, Uflowmeter(TM), allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS. OBJECTIVE * To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10-15, 15-19 and >19mL/s) at home, for the management of male lower urinary tract symptoms (LUTS). PATIENTS AND METHODS * A total of 186 men with LUTS were enrolled in the study. * The mean (range) follow-up was 220 (68-431) days. The men's mean (range) age was 65.5 (46-83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3-39.5) mL/s, mean (range) voided volume 294.8 (151-686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0-303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1-31). * The men underwent electronic uroflowmetry ('clinic uroflowmetry') and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home ('home uroflowetry'). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. * Quadratically weighted Kappa analysis ([kappa]) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10-15, 15-19 and >19mL/s) was performed. Similar analyses were performed for the IPSS. * Kaplan-Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP). RESULTS * The home uroflowmetry values ([kappa]= 0.84, 95% confidence interval [CI]: 0.78-0.90) were superior to the IPSS ([kappa]= 0.083; 95% CI: 0-0.173) in correlating with the mean Qmax of clinic uroflowmetry. * Home uroflowmetry was most sensitive in identifying a mean Qmax of >19mL/s (sensitivity: 0.99; 95% CI:0.97-1.00) and most specific in identifying a mean Qmax of <10mL/s (specificity: 0.90; 95% CI:0.83-0.94). * The home uroflowmetry works best in ruling out a mean Qmax of <19mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24-3037.7), followed by a mean Qmax of <15mL/s (DOR = 91.02; 95% CI:31.23-265.23) and a mean Qmax of <10mL/s (DOR = 32.04; 95% CI:14.0-73.19). * Men with a home uroflowmetry value ≤10mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10mL/s (n= 2; 1.7%) to develop AUR or require TURP (log-rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10-28.64)). The IPSS failed to display the same discriminative capability. CONCLUSION * Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS. [PUBLICATION ABSTRACT] Study Type - Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low-cost device, Uflowmeter(™) , allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS. To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10-15, 15-19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS). A total of 186 men with LUTS were enrolled in the study. The mean (range) follow-up was 220 (68-431) days. The men's mean (range) age was 65.5 (46-83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3-39.5) mL/s, mean (range) voided volume 294.8 (151-686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0-303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1-31). The men underwent electronic uroflowmetry ('clinic uroflowmetry') and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home ('home uroflowetry'). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10-15, 15-19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS. Kaplan-Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP). The home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78-0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0-0.173) in correlating with the mean Qmax of clinic uroflowmetry. Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97-1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83-0.94). The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24-3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23-265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0-73.19). Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log-rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10-28.64)). The IPSS failed to display the same discriminative capability. Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS. |
Author | Chan, Ning‐Hong Wu, Irene P.H. Li, Miu‐Ling Chan, Chi‐Kwok Yip, Sidney Kam‐Hung |
Author_xml | – sequence: 1 givenname: Chi‐Kwok surname: Chan fullname: Chan, Chi‐Kwok – sequence: 2 givenname: Sidney Kam‐Hung surname: Yip fullname: Yip, Sidney Kam‐Hung – sequence: 3 givenname: Irene P.H. surname: Wu fullname: Wu, Irene P.H. – sequence: 4 givenname: Miu‐Ling surname: Li fullname: Li, Miu‐Ling – sequence: 5 givenname: Ning‐Hong surname: Chan fullname: Chan, Ning‐Hong |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25918768$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21933332$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkcFuGyEQhlGVqEmcvkKFVFXqxRtYljVcKrVR2qSK1Esj5YYwHlosYF1gm_jtyzp2K-WUuTBivhmG_z9DR3GIgBCmpKE1LtYN7fpu3lFy37SE0oYSLmjz-Aqd_iscHXIi-xN0lvOakHrR89fopKWS1WhPUbj6o_2oixsiHiwuvwAb76Iz2uOpAtOtxtmFjQds_fAQoEDCLu7YoKP-CQFimbigK1ORWh-TizptcUnaFJy3YVOGkM_RsdU-w5v9OUN3X65-XF7Pb79_vbn8dDs3XSvoHCi3ZEE0W5meStsaA0QK2WrLDXRES24YE0JSIyxbUC1JJ_iCL8Eu5arlnM3Qh6e5mzT8HiEXFVw24L2OMIxZ0aqZ4GTSYIbePUPXw5hi3U5RxhnrJG8n6u2eGpcBVmqTXKjfUwchK_B-D-hctbNJR-Pyf45LKha9qNzHJ86kIecEVhlXdvJXpZyvm6nJYbVWk3lqMlJNDqudw-qxDhDPBhzeeEHr_u0H52H74j71-dvdLmV_ASNuvNw |
CODEN | BJINFO |
CitedBy_id | crossref_primary_10_1007_s00345_019_02907_3 crossref_primary_10_1007_s40846_018_0375_0 crossref_primary_10_1016_j_urology_2020_08_027 crossref_primary_10_1097_MOU_0b013e32835bb149 crossref_primary_10_1136_bmjopen_2021_056234 crossref_primary_10_1007_s00120_017_0547_5 crossref_primary_10_1016_j_jpurol_2024_07_007 crossref_primary_10_4081_aiua_2022_2_169 crossref_primary_10_1016_j_fjurol_2024_102846 crossref_primary_10_1007_s11255_014_0733_y crossref_primary_10_1007_s41973_020_00103_0 crossref_primary_10_1016_j_purol_2022_07_142 |
Cites_doi | 10.1111/j.1464-410X.1993.tb00684.x 10.1016/j.jclinepi.2004.12.009 10.1046/j.1464-410X.1996.00097.x 10.1016/S1569-9056(04)90343-0 10.1002/(SICI)1520-6777(1999)18:1<25::AID-NAU5>3.0.CO;2-O 10.1016/S0090-4295(01)01298-5 10.1002/nau.20383 10.1046/j.1464-410X.1996.00115.x 10.1037/1082-989X.1.2.150 10.5489/cuaj.09092 10.1016/S0022-5347(17)38458-6 10.4103/0970-1591.32058 10.1002/(SICI)1520-6777(1999)18:3<183::AID-NAU4>3.0.CO;2-I 10.1016/j.eursup.2009.02.001 10.1016/S0022-5347(17)35482-4 10.1016/j.eururo.2006.09.019 10.1016/j.eursup.2009.02.002 10.1016/S0094-0143(21)00966-6 10.1016/S0895-4356(03)00177-X 10.1016/j.urology.2006.03.035 10.1056/NEJMoa030656 10.1136/emj.20.5.453 10.1097/00042307-200007000-00008 10.1093/ptj/85.3.257 10.1016/S0022-5347(01)64508-7 10.1136/bmj.296.6627.965 10.1007/BF00182666 10.1136/bmj.298.6667.156 10.1016/S0022-5347(05)68271-7 10.1111/j.1464-410X.1976.tb06719.x |
ContentType | Journal Article |
Copyright | 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL 2015 INIST-CNRS 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. |
Copyright_xml | – notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL – notice: 2015 INIST-CNRS – notice: 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7X8 |
DOI | 10.1111/j.1464-410X.2011.10581.x |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Calcium & Calcified Tissue Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1464-410X |
EndPage | 1696 |
ExternalDocumentID | 2975456781 21933332 25918768 10_1111_j_1464_410X_2011_10581_x BJU10581 |
Genre | article Research Support, Non-U.S. Gov't Controlled Clinical Trial Journal Article |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OB 1OC 23N 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFNX AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX CITATION IQODW AAHHS ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CGR CUY CVF ECM EIF NPM 7QP 7X8 |
ID | FETCH-LOGICAL-c4281-e15f070a3dc619f2cce09892af5ce40a95c338891c8f371a9048575befb9d2553 |
IEDL.DBID | DR2 |
ISSN | 1464-4096 1464-410X |
IngestDate | Wed Oct 01 10:00:30 EDT 2025 Sun Jul 13 04:11:36 EDT 2025 Thu Apr 03 07:09:32 EDT 2025 Mon Jul 21 09:15:06 EDT 2025 Thu Apr 24 22:52:30 EDT 2025 Wed Oct 01 04:28:51 EDT 2025 Sun Sep 21 06:23:46 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | Evaluation Nephrology Urinary system disease Male Urinary tract disease LUTS Uflow-meter Urology Voiding dysfunction Sensitivity Specificity diagnostic odds ratio Clinical management uroflowmetry Ratio Diagnosis Lower urinary tract symptoms |
Language | English |
License | CC BY 4.0 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4281-e15f070a3dc619f2cce09892af5ce40a95c338891c8f371a9048575befb9d2553 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 |
PMID | 21933332 |
PQID | 1353349523 |
PQPubID | 1026371 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1011850333 proquest_journals_1353349523 pubmed_primary_21933332 pascalfrancis_primary_25918768 crossref_citationtrail_10_1111_j_1464_410X_2011_10581_x crossref_primary_10_1111_j_1464_410X_2011_10581_x wiley_primary_10_1111_j_1464_410X_2011_10581_x_BJU10581 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | June 2012 |
PublicationDateYYYYMMDD | 2012-06-01 |
PublicationDate_xml | – month: 06 year: 2012 text: June 2012 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England – name: Edgecliff |
PublicationTitle | BJU international |
PublicationTitleAlternate | BJU Int |
PublicationYear | 2012 |
Publisher | Blackwell Publishing Ltd Wiley-Blackwell Wiley Subscription Services, Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell – name: Wiley Subscription Services, Inc |
References | 1997; 158 2006; 50 2010; 14 1990; 17 1995; 13 1989; 298 2005; 85 2004; 3 1999; 162 1991 1976; 48 1996; 78 1996; 77 2003; 56 2003; 349 1991; 145 1993; 72 2006; 68 1999; 18 2000; 10 1993; 150 2009; 8 1996; 1 1988; 296 2010; 4 2007; 23 2001; 58 2003; 20 2007; 26 2005; 58 e_1_2_8_27_2 e_1_2_8_28_2 Chan CK (e_1_2_8_10_2) 2010; 14 e_1_2_8_29_2 Siroky MB (e_1_2_8_2_2) 1990; 17 e_1_2_8_23_2 e_1_2_8_24_2 e_1_2_8_25_2 e_1_2_8_26_2 e_1_2_8_9_2 e_1_2_8_3_2 e_1_2_8_6_2 e_1_2_8_5_2 e_1_2_8_8_2 e_1_2_8_7_2 e_1_2_8_20_2 e_1_2_8_21_2 e_1_2_8_22_2 e_1_2_8_16_2 e_1_2_8_17_2 e_1_2_8_18_2 e_1_2_8_19_2 e_1_2_8_12_2 e_1_2_8_13_2 e_1_2_8_14_2 e_1_2_8_15_2 Rollema HJ (e_1_2_8_4_2) 1991 e_1_2_8_31_2 e_1_2_8_30_2 e_1_2_8_33_2 e_1_2_8_11_2 e_1_2_8_32_2 |
References_xml | – volume: 48 start-page: 681 year: 1976 end-page: 4 article-title: Excretion urography in the investigation of prostatism publication-title: Br J Urol – volume: 3 start-page: 88 year: 2004 article-title: Baseline measures as predictors of clinical progression of benign prostatic hyperplasia publication-title: Eur Urol Suppl – volume: 26 start-page: 474 year: 2007 end-page: 80 article-title: Flow measurements: can several ‘wrongs’ make a ‘right’? publication-title: Neurourol Urodyn – volume: 50 start-page: 1306 year: 2006 end-page: 14 article-title: Population‐based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of EPIC study publication-title: Eur Urol – volume: 4 start-page: 123 year: 2010 end-page: 7 article-title: The aging male population and medical care for benign prostatic hyperplasia in Canada publication-title: Can Urol Assoc J – volume: 145 start-page: 810 year: 1991 end-page: 2 article-title: Bladder outlet obstruction versus impaired detrusor contractility: the role of outflow publication-title: J Urol – volume: 17 start-page: 537 year: 1990 end-page: 42 article-title: Interpretation of urinary flow rates publication-title: Urol Clin North Am – volume: 349 start-page: 2387 year: 2003 end-page: 98 article-title: The long‐term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia publication-title: N Engl J Med – volume: 298 start-page: 156 year: 1989 end-page: 9 article-title: Late renal failure due to prostatic outflow obstruction: a preventable disease publication-title: BMJ – volume: 150 start-page: 351 year: 1993 end-page: 8 article-title: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign hyperplasia publication-title: J Urol – volume: 72 start-page: 181 year: 1993 end-page: 6 article-title: How reliable is a single measurement of urinary flow in the diagnosis of obstruction in benign prostatic hyperplasia publication-title: Br J Urol – volume: 10 start-page: 337 year: 2000 end-page: 42 article-title: The aging male: a challenge for urologists publication-title: Curr Opin Urol – volume: 158 start-page: 481 year: 1997 end-page: 7 article-title: Natural history of prostatism: risk factors for acute urinary retention publication-title: J Urol – volume: 296 start-page: 965 year: 1988 end-page: 7 article-title: Prostatism: how useful is routine imaging of the urinary tract? publication-title: Br Med J (Clin Res Ed) – volume: 18 start-page: 183 year: 1999 end-page: 91 article-title: Low reproducibility of maximum urinary flow rate determined by portable flowmetry publication-title: Neurourol Urodyn – volume: 56 start-page: 1129 year: 2003 end-page: 35 article-title: The diagnostic odds ratio: a single indicator of test performance publication-title: J Clin Epidemiol – volume: 13 start-page: 47 year: 1995 end-page: 58 article-title: Analysis of bladder‐outlet function with the linearized passive urethral resistance relation, linPURR, and a disease‐specific approach for grading obstruction: from complex to simple publication-title: World J Urol – volume: 14 start-page: S23 year: 2010 article-title: UflowmeterTM – a simple, low‐cost and valid device to categorize different flow rates with high accuracy – an experimental laboratory verification study publication-title: Surg Pract – volume: 8 start-page: 523 year: 2009 end-page: 9 article-title: Management of acute and chronic retention in men publication-title: Eur Urol Suppl – volume: 78 start-page: 385 year: 1996 end-page: 90 article-title: Improved reliability of uroflowmetry investigations: results of a portable home‐based uroflowmetry study publication-title: Br J Urol – volume: 1 start-page: 150 year: 1996 end-page: 3 article-title: Sample size calculations for Cohen's Kappa publication-title: Psychol Methods – volume: 20 start-page: 453 year: 2003 end-page: 8 article-title: An introduction to power and sample size estimation publication-title: Emerg Med J – volume: 77 start-page: 813 year: 1996 end-page: 8 article-title: The value of multiple free‐flow studies in men with lower urinary tract symptoms publication-title: Br J Urol – volume: 58 start-page: 5 issue: 1 year: 2001 end-page: 16 article-title: Natural history of benign prostatic hyperplasia publication-title: Urology – volume: 58 start-page: 859 year: 2005 end-page: 62 article-title: Sample size calculation should be performed for design accuracy in diagnostic test studies publication-title: J Clin Epidemiol – volume: 18 start-page: 25 year: 1999 end-page: 32 article-title: Home uroflowmetry: improved accuracy in outflow assessment publication-title: Neurourol Urodyn – volume: 23 start-page: 114 year: 2007 end-page: 8 article-title: Clinical evaluation of a simple uroflowmeter for categorization of maximum urinary flow rate publication-title: Indian J Urol – start-page: 201 year: 1991 end-page: 44 – volume: 8 start-page: 496 year: 2009 end-page: 503 article-title: Medical treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia publication-title: Eur Urol Suppl – volume: 68 start-page: 560 year: 2006 end-page: 4 article-title: Epidemiologic survey of lower urinary tract symptoms in Japan publication-title: Urology – volume: 85 start-page: 257 year: 2005 end-page: 68 article-title: The kappa statistic in reliability studies: use, interpretation, and sample size requirements publication-title: Phys Ther – volume: 162 start-page: 1301 year: 1999 end-page: 6 article-title: Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status publication-title: J Urol – ident: e_1_2_8_3_2 doi: 10.1111/j.1464-410X.1993.tb00684.x – ident: e_1_2_8_15_2 doi: 10.1016/j.jclinepi.2004.12.009 – ident: e_1_2_8_28_2 doi: 10.1046/j.1464-410X.1996.00097.x – volume: 14 start-page: S23 year: 2010 ident: e_1_2_8_10_2 article-title: UflowmeterTM – a simple, low‐cost and valid device to categorize different flow rates with high accuracy – an experimental laboratory verification study publication-title: Surg Pract – ident: e_1_2_8_20_2 doi: 10.1016/S1569-9056(04)90343-0 – ident: e_1_2_8_25_2 doi: 10.1002/(SICI)1520-6777(1999)18:1<25::AID-NAU5>3.0.CO;2-O – ident: e_1_2_8_16_2 doi: 10.1016/S0090-4295(01)01298-5 – ident: e_1_2_8_26_2 doi: 10.1002/nau.20383 – ident: e_1_2_8_29_2 doi: 10.1046/j.1464-410X.1996.00115.x – ident: e_1_2_8_12_2 doi: 10.1037/1082-989X.1.2.150 – ident: e_1_2_8_5_2 doi: 10.5489/cuaj.09092 – ident: e_1_2_8_33_2 doi: 10.1016/S0022-5347(17)38458-6 – ident: e_1_2_8_13_2 doi: 10.4103/0970-1591.32058 – ident: e_1_2_8_27_2 doi: 10.1002/(SICI)1520-6777(1999)18:3<183::AID-NAU4>3.0.CO;2-I – ident: e_1_2_8_18_2 doi: 10.1016/j.eursup.2009.02.001 – ident: e_1_2_8_17_2 doi: 10.1016/S0022-5347(17)35482-4 – ident: e_1_2_8_7_2 doi: 10.1016/j.eururo.2006.09.019 – ident: e_1_2_8_21_2 doi: 10.1016/j.eursup.2009.02.002 – volume: 17 start-page: 537 year: 1990 ident: e_1_2_8_2_2 article-title: Interpretation of urinary flow rates publication-title: Urol Clin North Am doi: 10.1016/S0094-0143(21)00966-6 – ident: e_1_2_8_30_2 doi: 10.1016/S0895-4356(03)00177-X – ident: e_1_2_8_8_2 doi: 10.1016/j.urology.2006.03.035 – start-page: 201 volume-title: Clinical Neurology year: 1991 ident: e_1_2_8_4_2 – ident: e_1_2_8_19_2 doi: 10.1056/NEJMoa030656 – ident: e_1_2_8_14_2 doi: 10.1136/emj.20.5.453 – ident: e_1_2_8_6_2 doi: 10.1097/00042307-200007000-00008 – ident: e_1_2_8_11_2 doi: 10.1093/ptj/85.3.257 – ident: e_1_2_8_32_2 doi: 10.1016/S0022-5347(01)64508-7 – ident: e_1_2_8_24_2 doi: 10.1136/bmj.296.6627.965 – ident: e_1_2_8_31_2 doi: 10.1007/BF00182666 – ident: e_1_2_8_22_2 doi: 10.1136/bmj.298.6667.156 – ident: e_1_2_8_9_2 doi: 10.1016/S0022-5347(05)68271-7 – ident: e_1_2_8_23_2 doi: 10.1111/j.1464-410X.1976.tb06719.x |
SSID | ssj0014665 |
Score | 2.0906749 |
Snippet | Study Type – Diagnostic (exploratory cohort)
Level of Evidence 3b
What's known on the subject? and What does the study add?
Electronic uroflowmetry reasonably... Study Type - Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably... Study Type - Diagnostic (exploratory cohort) Level of Evidence3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably... |
SourceID | proquest pubmed pascalfrancis crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1690 |
SubjectTerms | Aged Aged, 80 and over Biological and medical sciences Cohort Studies Confidence intervals diagnostic odds ratio Equipment Design Excretory system Flowmeters Humans Lower Urinary Tract Symptoms - diagnosis Lower Urinary Tract Symptoms - etiology Lower Urinary Tract Symptoms - therapy LUTS Male Medical sciences Men Middle Aged Nephrology. Urinary tract diseases Older people Predictive Value of Tests Prostatic Hyperplasia - complications Prostatic Hyperplasia - physiopathology Prostatic Hyperplasia - therapy Rheology - instrumentation Self Care - instrumentation specificity Uflow‐meter™ sensitivity Urinary Bladder Neck Obstruction - diagnosis Urinary Bladder Neck Obstruction - etiology Urinary Bladder Neck Obstruction - therapy Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland Urination - physiology Urodynamics - physiology uroflowmetry Urogenital system |
Title | Evaluation of the clinical value of a simple flowmeter in the management of male lower urinary tract symptoms |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2011.10581.x https://www.ncbi.nlm.nih.gov/pubmed/21933332 https://www.proquest.com/docview/1353349523 https://www.proquest.com/docview/1011850333 |
Volume | 109 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVEBS databaseName: Academic Search Ultimate - eBooks customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1464-410X dateEnd: 20241003 omitProxy: true ssIdentifier: ssj0014665 issn: 1464-4096 databaseCode: ABDBF dateStart: 19990101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1464-410X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014665 issn: 1464-4096 databaseCode: DIK dateStart: 19990101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1464-4096 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1464-410X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014665 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh1IofT-2SYMKvXqxLMmWj01ICIH0ULqwN2HrASFre6m99PHrOyN5HRxyCKU-GUsj9JiRvvGMZgj57IWRmStEYgqXJ0I6lijjbJKnziopRBFX-uprfrESl2u5Hv2f8C5MjA8x_XBDyQj7NQp4Vfd3hVwkgqXrGIkTkIJiS8STjMtgsf02RZKCqiGrZCQB2D536rm3odlJ9XRb9TBpPma7uA-OztFtOJ7On5Ob_cCiV8rNcjfUS_PnTszH_zPyF-TZiGLpl8h2L8kj174ij69GO_1r0pxNQcRp5ymATLq_gkmxxOHXivbXGJuY-k33s0G3HHrdhrrN5JOD9Ro4w-gGs7lRNA1Av-mAd7to_7vZDl3TvyGr87PvpxfJmNghMaDtsMQx6WGrqbg1oL_5zBiXlqrMKi-NE2lVSgOasyqZUZ4XrCphmwFYWTtflxZ0IP6WHLRd694TmmfWAqhRHpoTzvLSW1sVEmBJzXmt8gUp9ouozRj1HJNvbPRM-xEaZ1PjbOowm_rXgrCJchsjfzyA5njGJxMhKJkMzh21IEd7xtHjZtFrTD3CQVHN-IJ8mopBzNF2U7Wu2_XoiQfIKuUc6ryLDHfbOIBweDIYa2CbB3dXn1yuwuuHf6Y8JE_gexad547IwfBj5z4CTBvq4yCAfwGx3ixg |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhbYQ0nezbZqq0KsXy5Jt-dhHwjbN5lCysDdh6wEha3uJvaTNr--M5XVxyCGU-mSsGSHJM9I30miGkE9O6DiyqQh0apNAxJYFUlsTJKE1MhYi9X96fpbMFuJkGS_7dEB4F8bHhxg23FAzuvkaFRw3pG9ruQgEC5c-FCdABcmmACgf4nEdaum3n0MsKaDt8kp6HgDuY7eeO2sarVW767yBYXM-38VdgHSMb7sF6vgpWW275v1SLqebtpjqm1tRH_9T35-RvR7I0s9e8p6TB7Z6QR7N-6P6l6Q8GuKI09pRwJl0ewuTYonFrzltLjA8MXWr-rpEzxx6UXW05eCWg3QlLGN0hQndKJ4OQMNpi9e7aPO7XLd12bwii-Oj86-zoM_tEGgweFhgWexgtsm50WDCuUhrG2Yyi3IXayvCPIs1GM8yY1o6nrI8g5kGkGVhXZEZMIP4a7JT1ZXdJzSJjAFcIx1UJ6zhmTMmT2NAJgXnhUwmJN3-RaX7wOeYf2OlRgaQUDiaCkdTdaOpfk0IGzjXPvjHPXgOR4IyMIKdyWDpkRNysJUc1c8XjcLsIxxs1YhPyMehGDQdj2_yytabBp3xAFyFnAPNGy9xfysHHA5PBH3t5ObezVVfThbd69t_5vxAHs_O56fq9PvZj3fkCdBE3pfugOy0Vxv7HlBbWxx22vgHfPYwfA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Za9wwEBYlgVAoTc900zRRoa9eLEu25cceWXI0oZQu7JuwdUDI2l5qL23z6ztjeV0c8hBK_GSsGaFjRvrGGs0Q8sEJHUc2FYFObRKI2LJAamuCJLRGxkKkfqYvLpOTuThbxIve_wnvwvj4EMMPN9SMbr1GBV8Zd1vJRSBYuPCROAEpSDYFPLktEjC2ECB9H0JJAW2XVtLzAG4fe_XcWdNoq3qyyhsYNefTXdyFR8fwttufZrvketMz75ZyPV23xVTf3Ar6-DBdf0ae9jCWfvRy95w8stULsnPRH9S_JOXxEEWc1o4CyqSbO5gUSyx-zWlzhcGJqVvWv0r0y6FXVUdbDk45SFfCJkaXmM6N4tkAtJu2eLmLNn_KVVuXzSsynx3_-HwS9JkdAg3mDgssix2sNTk3Ggw4F2ltw0xmUe5ibUWYZ7EG01lmTEvHU5ZnsM4AriysKzIDRhB_TbaqurJvCE0iYwDVSAfVCWt45ozJ0xhwScF5IZMJSTeTqHQf9hyzbyzVyPwRCkdT4WiqbjTV7wlhA-fKh_64B8_hSE4GRrAyGWw8ckIONoKj-tWiUZh7hIOlGvEJeT8Ug57j4U1e2XrdoCseQKuQc6DZ8wL3r3JA4fBE0NdObO7dXPXpbN697v835xHZ-fZlpr6eXp6_JY-BJPKOdAdkq_25tu8AsrXFYaeLfwGvEi8r |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+clinical+value+of+a+simple+flowmeter+in+the+management+of+male+lower+urinary+tract+symptoms&rft.jtitle=BJU+international&rft.au=CHAN%2C+Chi-Kwok&rft.au=KAM-HUNG+YIP%2C+Sidney&rft.au=WU%2C+Irene+P.+H&rft.au=LI%2C+Miu-Ling&rft.date=2012-06-01&rft.pub=Wiley-Blackwell&rft.issn=1464-4096&rft.volume=109&rft.issue=11&rft.spage=1690&rft.epage=1696&rft_id=info:doi/10.1111%2Fj.1464-410X.2011.10581.x&rft.externalDBID=n%2Fa&rft.externalDocID=25918768 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |